Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ASMB 
Assembly Biosciences Inc (ASMB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: ASMB (3-star) is a STRONG-BUY. BUY since 8 days. Simulated Profits (7.17%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $38.2
1 Year Target Price $38.2
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 56.9% | Avg. Invested days 32 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 458.24M USD | Price to earnings Ratio - | 1Y Target Price 38.2 |
Price to earnings Ratio - | 1Y Target Price 38.2 | ||
Volume (30-day avg) 2 | Beta 0.61 | 52 Weeks Range 7.75 - 31.12 | Updated Date 10/21/2025 |
52 Weeks Range 7.75 - 31.12 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -117.2% | Operating Margin (TTM) -115.24% |
Management Effectiveness
Return on Assets (TTM) -27.74% | Return on Equity (TTM) -147.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 109736585 | Price to Sales(TTM) 13.78 |
Enterprise Value 109736585 | Price to Sales(TTM) 13.78 | ||
Enterprise Value to Revenue 3.3 | Enterprise Value to EBITDA 0.42 | Shares Outstanding 7672261 | Shares Floating 3593610 |
Shares Outstanding 7672261 | Shares Floating 3593610 | ||
Percent Insiders 38.52 | Percent Institutions 25.66 |
Upturn AI SWOT
Assembly Biosciences Inc
Company Overview
History and Background
Assembly Biosciences, Inc. was founded in 2005 and is a biopharmaceutical company focused on developing innovative therapies targeting hepatitis B virus (HBV) infection and other viral diseases. It has evolved through research and development programs focused on HBV core inhibitors and other approaches to achieve HBV functional cure.
Core Business Areas
- HBV Drug Development: Focuses on the research and development of core inhibitors and other therapeutic candidates for the treatment of chronic HBV infection.
- Research and Development: Exploration of novel antiviral therapies and platform technologies.
Leadership and Structure
Jason Okazaki is the President and CEO. The company has a board of directors and an executive leadership team overseeing various functional areas like R&D, clinical development, and finance.
Top Products and Market Share
Key Offerings
- Vebicorvir (ABI-H0731): Was Assembly Biosciences' lead core inhibitor for HBV. Clinical trials were discontinued in 2023. Competitors included Gilead Sciences (Vemlidy), Enanta Pharmaceuticals, and Roche, which are pursuing similar HBV therapies. Market share data for Vebicorvir is not available due to trial discontinuation.
- ABI-4334: Novel investigational therapeutic being developed by Assembly. Market share information is not available because it is still under development.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. There is a significant unmet medical need for effective HBV therapies, driving innovation and investment in the field.
Positioning
Assembly Biosciences aims to develop a functional cure for HBV. However, the current competitive landscape is strong with large pharmaceutical companies having a dominant position.
Total Addressable Market (TAM)
The HBV therapeutics market is estimated to be worth billions of dollars annually. Assembly Biosciences seeks to capture a portion of this TAM with its investigational therapies.
Upturn SWOT Analysis
Strengths
- Focus on HBV therapeutics
- Experienced scientific team
- Novel core inhibitor technology
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High reliance on clinical trial outcomes
- Discontinuation of lead drug candidate (Vebicorvir) indicates high risk of the companyu2019s other investigational drugs
- Uncertainty regarding regulatory approval
Opportunities
- Partnerships with larger pharmaceutical companies
- Potential for breakthrough HBV therapies
- Expansion into other viral disease areas
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- GILD
- ABBV
- BMY
Competitive Landscape
Assembly Biosciences is a smaller player compared to established pharmaceutical giants like Gilead. It relies on innovation to compete.
Growth Trajectory and Initiatives
Historical Growth: Assembly Biosciences has experienced growth in R&D spending but has struggled for revenue growth. Stock performance has been volatile, especially after the discontinuation of the company's lead drug candidate.
Future Projections: Future growth is contingent on the success of current research programs. Analyst projections are estimates and subject to change.
Recent Initiatives: Recent initiatives include advancing new HBV drug candidates and exploring new therapeutic approaches.
Summary
Assembly Biosciences is a small biopharmaceutical company focused on innovative HBV therapies, but it discontinued its lead drug in 2023. It is high risk and R&D intensive, and its success depends on clinical trial outcomes. While the company faces strong competition, its focus on HBV and potential for breakthrough therapies offer growth opportunities. Investors should be aware of the inherent risks and financial challenges associated with Assembly Biosciences' development of investigational therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Assembly Biosciences Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2010-12-17 | CEO, President & Director Mr. Jason A. Okazaki J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 73 | Website https://www.assemblybio.com |
Full time employees 73 | Website https://www.assemblybio.com | ||
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.